Dual-listed (ASX and Nasdaq) regenerative medicine company Avita Medical (ASX ... of the WiSE CRT (cardiac resynchronisation therapy) system said the updated PAI schedule won’t affect the ...

Wound care company Avita Medical falls on downgrade of its earnings guidance EBR’s US FDA manufacturing pre-approval inspection scheduled for next week ASX health stocks up 1.88% over past week ...

Wound care company Avita Medical falls on downgrade of its earnings guidance EBR’s US FDA manufacturing pre-approval inspection scheduled for next week ASX health stocks up 1.88 ... resynchronisation ...

Valencia-based Avita Medical Inc. has received FDA approval for a version of its second-generation Recell skin cell ...

Stock analysts at Cantor Fitzgerald reduced their FY2024 EPS estimates for shares of AVITA Medical in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects ...

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...

Despite 30% growth, fundamentals remain concerning. Last week, AVITA's stock fell ~20% after reporting preliminary Q4 earnings. The company had been guiding for between $22.3 million and $24.3 ...

Avita, which specializes in wound care and skin restoration, anticipates fourth-quarter commercial revenue of approximately $18.4 million. It reflects a 30% year-over-year increase. However ...

No-moat Avita Medical downgraded its fourth-quarter 2024 commercial revenue guidance by 21% to USD 18 million. It now expects full-year commercial revenue of USD 64 million compared with its ...

AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales ...